Re-defining the limits of single batch assay stabilisation

In response to increasing demand for stabilised molecular diagnostic assays, we have significantly increased our single batch lyophilised reagent bead manufacturing throughput to 300,000 reactions per freeze drying run and are now progressing towards a capacity of 100 million tests per annum.

Single batch manufacturing of lyophilised beads

Biofortuna Limited

Utilising bespoke high precision automation, four dedicated freeze driers (each with 3.5m2 shelf capacity) housed in a 180m2 ISO-7, Class 10,000 clean room with humidity control at <2%RH, we are able to provide our customers with a range of lyo stable solutions including bulk reagent formulation, robotic liquid dispensing and a range of flexible packaging options and sub-assembly placement.

Our scalable manufacturing services support a range of clients from disruptive technology developers through to global point-of-care (POC) in vitro diagnostic (IVD) manufacturers. We work with complex formulations including next generation sequencing (NGS) reagents, micro-spheres, paramagnetic particles, latex and colloids including a wide range of bio-conjugation with enzymes, antibodies & molecular master mixes and probes”.

Lee Walker, Head of Technical Services.

Together with our on-site R&D team,  we offer a complimentary range of outsourced laboratory services that include genomicscustom development and ISO:13485 contract manufacturing services.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Biofortuna Limited. (2022, August 22). Re-defining the limits of single batch assay stabilisation. AZoLifeSciences. Retrieved on November 21, 2024 from https://www.azolifesciences.com/news/20220822/Re-defining-the-limits-of-single-batch-assay-stabilisation.aspx.

  • MLA

    Biofortuna Limited. "Re-defining the limits of single batch assay stabilisation". AZoLifeSciences. 21 November 2024. <https://www.azolifesciences.com/news/20220822/Re-defining-the-limits-of-single-batch-assay-stabilisation.aspx>.

  • Chicago

    Biofortuna Limited. "Re-defining the limits of single batch assay stabilisation". AZoLifeSciences. https://www.azolifesciences.com/news/20220822/Re-defining-the-limits-of-single-batch-assay-stabilisation.aspx. (accessed November 21, 2024).

  • Harvard

    Biofortuna Limited. 2022. Re-defining the limits of single batch assay stabilisation. AZoLifeSciences, viewed 21 November 2024, https://www.azolifesciences.com/news/20220822/Re-defining-the-limits-of-single-batch-assay-stabilisation.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.